LNS8801

LNS8801 · Linnaeus Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for LNS8801, covering 2025-12-18 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma [Phase 2, Phase 3]